Genia’s mission is to make genetic information universally available. Our proprietary integrated circuits and NanoTag chemistry enable massively parallel single-molecule DNA sequencing. This versatile nanopore-based platform allows for single molecule, electrical, real-time analysis without the need for complicated optics, labels, amplification, or fluidics. By developing a true integrated circuit on standard semiconductor process technology, Genia’s sequencing platform enables the use of molecular diagnostics in everyday clinical care.
Acquired by Roche for $350 Million, Genia is a nanopore sequencing company that was founded in 2009.